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Abstract
Background: Epitheliomesenchymal transition (EMT) is the process where cancer cells attain fibroblastic features
and are thus able to invade neighboring tissues. Transcriptional factors zeb1, snai1 and twist regulate EMT.
Methods: We used immunohistochemistry to investigate the expression of zeb1, twist and snai1 in tumor and
stromal compartments by in a large set of breast carcinomas. The results were compared with estrogen and
progesterone receptor status, HER2 amplification, grade, histology, TNM status and survival of the patients.
Results: Nuclear expression for twist was seen in the epithelial tumor cell compartment in 3.6% and for snai1 in 3.1%
of the cases while zeb1 was not detected at all in these areas. In contrast, the tumor stromal compartment showed
nuclear zeb1 and twist expression in 75% and 52.4% of the cases, respectively. Although rare, nuclear expression of
twist in the epithelial tumor cell compartment was associated with a poor outcome of the patients (p = 0.054 log
rank, p = 0.013, Breslow, p = 0.025 Tarone-Ware). Expression of snai1, or expression of zeb1 or twist in the stromal
compartment did not have any prognostic significance. Furthermore, none of these factors associated with the size
of the tumors, nor with the presence of axillary or distant metastases. Expression of zeb1 and twist in the stromal
compartment was positively associated with a positive estrogen or progesterone receptor status of the tumors.
Stromal zeb1 expression was significantly lower in ductal in situ carcinomas than in invasive carcinomas (p = 0.020).
Medullary carcinomas (p = 0.017) and mucinous carcinomas (p = 0.009) had a lower stromal expression of zeb1 than
ductal carcinomas. Stromal twist expression was also lower in mucinous (p = 0.017) than in ductal carcinomas.
Conclusions: Expression of transcriptional factors zeb1 and twist mainly occur in the stromal compartment of
breast carcinomas, possibly representing two populations of cells; EMT transformed neoplastic cells and stromal
fibroblastic cells undergoing activation of zeb1 and twist due to growth factors produced by the tumor. However,
epithelial expression of twist was associated with a poor prognosis, hinting at its importance in the spread of
breast carcinoma.
Background
Epitheliomesenchymal transition (EMT) is a process
where epithelial cells attain fibroblastic properties. It has
been postulated that in this way carcinoma cells are bet-
ter able to invade to the surrounding structures and
metastasize [1,2]. EMT is characterised by a downregu-
lation of adhesion molecules, such as E-cadherin, and
upregulation of genes typically found in myofibroblastic
or fibroblastic cells such as a-smooth muscle actin or
vimentin [1,2]. EMT is regulated by several transcription
factors, such as snai1, slug, zeb1, twist, CarB-box-bind-
ing factor, Mesenchyme Forkhead 1 and Kruppel-like
factor [2]. The expression of these transcription factors
is modified and regulated by complex signaling networks
present in the tumor microenvironment such as trans-
forming growth factor b, notch or Wnt pathways [3].
There appears to be a hierarchy in the expression of
these transcriptional factors, with snai1 being expressed
at the onset of EMT whereas snai2, zeb1 and twist are
induced later to maintain the migratory phenotype [3].
Zeb1 (Zinc-finger E-box-binding homeobox 1) is a
transcriptional factor which contains two Kruppel-type
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zinc finger domains by which it becomes attached to
target DNA sequences [4,5]. It induces EMT and has
been shown to downregulate E-cadherin in epithelial
cells [5]. Zeb1 also downregulates the polarity factor
lethal giant larvae 2 (Lgl2) in colon cancer cell lines and
promotes colon cancer cell metastasis [6]. It takes part
in morphogenesis during the embryonic development by
influencing the development of neural tissues, chondro-
cytes, skeletal muscle cells and hematolymphoid tissues
[7]. Zeb1 is induced by transforming growth factor b1
and nuclear factor kappa beta (NF-kb), it is unregulated
by the hedgehog signalling pathway, its expression is
influenced by hypoxia, but suppressed by the micro
RNA miR-200 family [4,8,9]. Zeb1 expression is also
induced by estrogen and progesterone [4]. In normal tis-
sues, zeb1 mRNA expression is highest in bladder and
uterus, but during embryonic development the highest
mRNA levels are found in heart, lung and thymus [4].
Twist is a helix-loop-helix transcriptional factor which
is known to promote EMT and downregulate E-cadherin
[10]. It is important in head and limb development and a
mutation of the twist gene causes the Saethre-Chotzen
syndrome [11]. In hepatic carcinoma cell lines, twist
induces cell motility and abrogates cellular adhesion and
metastasis [10,12]. On the other hand, downregulation of
twist by small interfering RNA (siRNA) in prostate carci-
noma cells leads to a decreased metastatic potential and
invasion of the tumor cells [13].
Snai1 is a transcriptional factor which downregulates
the expression of E-cadherin, claudin 1 and cytokeratin
18 and upregulates vimentin and in this way it can con-
tribute to EMT [14,15]. It is regulated by transcriptional
factors such as NF-kappaB [16]. In mouse skin squamous
cell carcinomas, its downregulation leads to retarded
growth and invasiveness of the cancer cells [17]. Conver-
sely, upregulation of snai1 expression is associated with a
poor prognosis and metastatic potential in patients with
ovarian or head and neck carcinomas [14,18]. In addition
to being important in EMT and tumor invasion, snai1
plays a role in embryonic development and it can influ-
ence apoptosis, angiogenesis and matrix metalloprotei-
nase 9 (MMP9) expression, i.e. factors which are
important in promoting tumor growth [19,20].
Several cell line studies have shown that these tran-
scriptional factors induce EMT and in this way can pro-
mote the metastatic potential of the malignant cells. In
this study, we investigated the expression of zeb1, twist
and snail in epithelial tumor and stromal compartments
in a large prospective set of breast carcinomas to eluci-
date whether these factors are important in the spread
of breast tumor cells in vivo. We used a tissue array
material consisting originally of 556 breast carcinomas
as the target material of which 511 were invasive and 45
of in situ type. The results were compared with the
estrogen (ER) and progesterone receptor (PR) status,
HER2 amplification, grade, histology, stage and survival
of the patients.
Methods
Materials
The material consisted of 388 cases of invasive and in
situ carcinomas. The details of the characteristics of the
material are shown in Table 1. The material was collected
from the files of the Kuopio University Hospital, Kuopio,
Finland. All material had been fixed in 4% buffered for-
malin and embedded in paraffin. The slides were viewed
and array blocks were constructed from representative
areas of the tumors with at least one array sample repre-
senting the invasive front. The array blocks were con-
structed with a custom-built instrument (Beecher
Instruments, Silver Spring, MD). The sample diameter of
the tissue core in the array block was 1300 μm and three
samples from tumor tissue of each case were studied.
The diagnosis of the cases was based on the World
Health Organization (WHO) classification of breast and
female genital organs [21]. The presence of metastases
was determined at the time of the operation. The collec-
tion of the material and the clinical features of the
patients have been described in a previous study [22].
The research was approved by the ethical committee of
Kuopio University and Kuopio University Hospital.
According to Finnish legislation no informed consent to
use paraffin embedded material in research is not needed
from subjects if the material is large and retrospective, in
such cases the consent can instead be applied from the
National Supervisory Authority for Welfare and Health
of Finland http://www.valvira.fi/; http://www.finlex.fi/fi/
laki/ajantasa/2001/20010594. The consent to use the
material was obtained from that institution.
Immunohistochemistry for zeb1, twist and snai1
The immunostainings were performed as follows. Four-
μm-thick tissue sections were cut from the paraffin-
embedded blocks. After deparaffinisation and rehydration,
the sections were heated in a microwave oven for 2 ×
5 min in Trisaminomethane-Ethylenediaminetetraacetic
Acid (Tris-EDTA) buffer (pH 9.0), incubated in a Tris-
EDTA buffer for 20 min and washed twice for 5 min in
phosphate buffered saline (PBS). Hydrogen peroxide (5%,
5 min) was used to block endogenous peroxidase. Non-
specific binding was blocked with 1.5% normal serum in
PBS for 35 min at room temperature. The sections were
incubated overnight at 4°C with the mouse monoclonal
anti - SnaiI, twist and zeb1 antibodies (dilutions 1:1000,
1:500 and 1:500, respectively). The twist antibody was pur-
chased from Abcam (ab50887, Abcam, Cambridge, UK)
and the mouse monoclonal zeb1 antibody from GenWay
(clone 416A7H10, San Diego, CA, USA). The snai1
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antibody has been characterised previously [23,24]. The
slides were then incubated with a biotinylated secondary
antibody and avidin-biotin-peroxidase complex (ABC Vec-
tastain Elite Kit, Vector Laboratories, Burlingame, CA,
USA). Careful rinses were performed with PBS at each
step of the immunostaining procedure. The color was
developed with diaminobenzidine tetrahydrochloride
(DAP) (Sigma, St. Louis, MO, USA). The slides were
counterstained with Mayer’s haematoxylin, washed, dehy-
drated, cleared and mounted with Depex (BDH, Poole,
UK). Ovarian tumor tissue with known positive Snail1,
twist or zeb1 expression was used as a positive control. In
the negative controls, the primary antibody was omitted.
The immunoreactivity for zeb1, twist and snail was
separately analysed in the stromal fibroblastic and
epithelial cell compartments of the tumor. Only nuclear
positivity was considered significant. The immunoreac-
tivity for fusiform stromal cells was semiquantified as
follows;
0-5% = negative (0)
5-25% = weak positivity (1)
25-50% = moderate positivity (2)
50-75% = strong positivity (3)
75-100% = very strong positivity (4)
For epithelial tumor cells, only the presence of nuclear
negativity (0) or positivity (1) was assessed.
The evaluation was performed by two pathologists
(YS, RS) from three separate array samples. The med-
ian expression of zeb1 in nuclei of fusiform stromal
cells was 1.6, and 1.3 for twist using the evaluation cri-
teria presented above. For snai1, no stromal nuclear
positivity was observed. These values were used as
dividing points when separating the materials into two
groups; low expression = 0 or high expression (1) (see
Tables 2, 3, 4).
Statistical analysis
The statistical analyses were performed with SPSS for
Windows software (SPSS, Chicago, IL, USA). Continu-
ous data were compared using analysis of variance
(ANOVA). When ANOVA results indicated that groups
differed, post hoc comparisons were performed using
two-tailed t-tests. Categorical data were compared using
Fisher’s exact test designed for small sample groups.
Correlations were studied with Pearson´s correlation.
Survival-data was analyzed using the Kaplan-Meier
method with the use of the log-rank, Breslow and Tar-
one-Ware test. P-values less than 0.05 were considered
statistically significant.
Results
No expression for zeb1 was found in breast cancer cells
in the epithelial compartment (Figure 1). With twist and
snai1, 14/387 (3.6%) and 12/387 (3.1%) showed nuclear
positivity in epithelial cancer cells, respectively (Figure 2
and 3). In contrast, nuclear positivity in fusiform stromal
cells was found in 260/347 (75.0%) for zeb1 and 187/357
(52.4%) for twist but with snai1, no evident nuclear posi-
tivity was detected in stromal fusiform cells (Table 1)
(Figure 1 and 4). In the three separate array samples,
the evaluations for zeb1, snai1 and twist correlated
strongly positively (R = 532-613, p < 0.001 for all assess-
ments). The interobserver variation for evaluation of
stromal and nuclear expression was good (kappa =
0.548, p < 0.001).
Expression in the stromal compartment
There was a significant positive association between
zeb1 and twist expressions in stromal fusiform cells in
breast carcinoma (p < 0.001) with stromal zeb1being
significantly lower in ductal in situ carcinomas than in
invasive carcinomas (p = 0.020). Medullary carcinomas
(p = 0.017) and mucinous carcinomas (p = 0.009) had a
lower stromal expression of zeb1 than ductal carcino-
mas. Stromal twist expression was also lower in muci-
nous carcinomas (p = 0.017) than in ductal carcinomas.
In the whole material, stromal zeb1 was associated
with a positive estrogen (p = 0.003) and progesterone
receptor status (p = 0.006) and inversely with HER2
amplification (p = 0.037) (Table 2 and 3). Stromal twist
was also associated with a positive estrogen (p = 0.018)
and progesterone receptor status (p = 0.009) (Table 2
Table 1 Data on the breast carcinoma cases studied
Histology In situ ductal invasive lobular invasive mucinous medullary others
16 252 70 19 8 23
Positive Negative
ER 279 87
PR 230 150
Her2 47 299
N0 N>0
217 165
T≤2 T>2
352 36
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and 3) but no association was found with HER2 (p =
0.14) Stromal zeb1 and twist did not associate with the
presence of axillary metastases or the size of the tumors
(p = 0.316 and p = 0.257)). There were more cases with
weak stromal zeb1 positivity in grade I than in grade II
tumors (p = 0.011). No such association was found for
twist (p = 0.24). Interestingly, however, grade III tumors
showed less stromal zeb1 positivity than grade II carci-
nomas (p = 0.001). No association was found between
cytokeratin 5/6 and stromal zeb1 or twist expression (p
= 0.923 and p = 0.952).
If HER2 positive cases were omitted from the analysis,
then stromal zeb1 and twist positivities were still asso-
ciated with a positive ER status (p = 0.010 and 0.015,
respectively) and progesterone receptor status (p =
0.008 and 0.007, respectively). Stromal zeb1 was more
commonly associated with grade I-II than grade III
tumors (p = 0.042). Interestingly, no HER positivity in
HER amplified cases was seen in the stromal cells sug-
gesting that no positive evidence of EMT could be
established in these cases.
Expression in the epithelial compartment
Nuclear twist positivity in the epithelial carcinoma com-
partment was found in 7 ductal invasive, 4 lobular inva-
sive, 1 tubular, 1 non-specified and one ductal
carcinoma in situ. Most of the positive tumors were of
grade II. No association was found with stromal twist or
zeb1 positivity. There was no association with the estro-
gen receptor (p = 0.36) or HER2 status (p = 0.22). With
the progesterone receptor, there was a near significant
inverse association (p = 0.051). There was no association
with the size of the tumor (p = 0.277) or axillary nodal
status (p = 0.20).
Nuclear snai1 positivity in carcinoma cells was found
in 7 ductal invasive, one lobular invasive, one mixed
tubulolobular and one mucinous carcinoma. No signifi-
cant association was found between snai1 and twist
positivity (p = 0.638). Snai1 was inversely associated
with a positive estrogen receptor status (p = 0.041), but
not with the progesterone receptor (p = 0.58) nor with
the size of the tumor (p = 0.301), presence of metastases
(p = 0.57), grade of tumor (P = 0.10, grade I-II/III) or
HER2 amplification (p = 0.215).
Survival analysis
In the whole material expression of zeb1 or twist in
the stromal compartment did not associate with over-
all survival (p = 0.600 log rank, p = 0.668 log rank,
respectively). Nuclear twist expression in the epithelial
compartment was, however, associated with a poorer
outcome of the patients (p = 0.054 log rank, p =
0.013, Breslow, p = 0.025 Tarone-Ware). (Figure 5)
Nuclear snail expression in the epithelial compartment
did not associate with survival (p = 0.96, log rank). In
summary, nuclear snai1 and twist positivity had an
association with survival in HER2 negative tumors
(p = 0.065, log rank, p = 0.026, Breslow, p = 0.039
Tarone-Ware).
Discussion
This study was undertaken to analyse the expression
and role of transcription factors zeb1, twist and snai1 in
human breast carcinoma. The study shows that nuclear
expression of these transcription factors in breast carci-
noma epithelial tumor cell compartment is uncommon
with only 3.6% and 3.1% of cases being positive for twist
and snai1 and with no positivity for zeb1. The cells in
the stromal compartment, however, showed abundant
nuclear positivity for zeb1 and twist, though no positive
cases with snai1 were found where nuclear expression of
fusiform stromal cells would have exceeded the 5%
Table 2 Expression of zeb1, twist and snai1 in breast carcinoma
Stromal compartment zeb1 Twist Snail Epithelial compartment zeb1 Twist Snail
High expression 188 135 0 Positive 0 14 12
Low expression 194 252 0 Negative 0 373 387
High expression > median value in estimations (see materials and methods).
Low expression ≤ median value in estimations (see materials and methods).
Table 3 Stromal expression of zeb1 and twist in relation
to the estrogen receptor status in breast cancer
zeb1
stroma
ER+ ER- Twist
stroma
ER+ ER-
High expression 147 30 109 22
Low expression 128 56 169 65
P = 0.003 P = 0.018
High expression > median value in estimations (see materials and methods).
Low expression ≤ median value in estimations (see materials and methods).
Table 4 Stromal expression of zeb1 and twist in relation
to the progesterone receptor in breast cancer
zeb1
stroma
PR+ PR- Twist
stroma
PR+ PR-
High expression 128 56 94 39
Low expression 100 92 135 111
P < 0.001 P = 0.003
High expression > median value in estimations (see materials and methods).
Low expression ≤ median value in estimations (see materials and methods).
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expression level considered as the limit for positive
expression.
The low expression of zeb1, twist and snai1 in epithe-
lial tumor cell compartment of breast carcinoma is sur-
prising since these transcriptional factors are believed to
be important in the spread of carcinomas through induc-
tion of EMT. Similar findings have been found in pan-
creatic adenocarcinomas where twist expression was
lower in tumor cells than in non-neoplastic epithelial
cells [25]. However, EMT is defined as a phenomenon
where tumor cells lose their epithelial features, and thus
a proportion of the cells in stromal tissue might represent
transformed malignant cells. In fact, during EMT, epithe-
lial cancer cells have been postulated to be transformed
to mesenchymal type cells then invade the blood vessels
or lymphatics after which they regain epithelial features
at a metastatic site through mesenchymal-epithelial
transformation [26]. Evidence for this kind of concept
comes from the detection of similar genetic changes in
both tumor and stromal cells in primary tumor sites
while in metastases, stromal cells do not display these
kinds of genetic changes [26]. Furthermore, epithelial
cells have been shown to transdifferentiate to myofibro-
blastic cells in tissue fibrosis and cancer [27,28]. Our
results could thus merely indicate that epithelial tumor
cells initiate zeb1 and twist synthesis after being trans-
formed to myoepithelial type cells. This is in line with
the proposed hierarchy of the expression of such
Figure 1 Expression of zeb1 in breast carcinoma. Strong nuclear
expression is found in the stromal compartment while cells in the
epithelial compartent are negative. The positive nuclei in stroma,
however, show variation in size and display conspicuous nucleoli.
Figure 2 Expression of twist in breast carcinoma. In this case of
a breast carcinoma, strong nuclear expression of twist is found in
nuclei of the epithelial cell compartment of the cells.
Figure 3 Expression of snai1 in breast carcinoma. Tumor cells
show nuclear expression in the epithelial compartment while
fusiform stromal cells are negative. There is some cytoplasmic
positivity in both tumor and stromal cells.
Figure 4 Expression of twist in breast carcinoma. In this case
nuclear expression is found in the stromal compartment while
epithelial tumor cells are negative.
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transcriptional factors in EMT [3,28] leading to that zeb1
and twist, which apparently maintain the migratory phe-
notype of tumor cells, are mostly detected in the stromal
compartment in breast tumor tissue. On the other hand,
evidently stromal fibroblast-derived cells are also acti-
vated to express zeb1 and twist which makes it difficult
to differentiate these cell types from each other by mor-
phologic means, a phenomenon which has also been
described by others [28].
Even though the low frequency of cases with nuclear
expression in epithelial type tumor cells, twist expres-
sion in these cells has clinical importance in breast car-
cinoma. Nuclear expression of twist was related to a
poorer outcome of the patients. It has been shown pre-
viously that downregulation of twist in aggressive breast
cancer cell lines leads to an abrogation of the invasive
and metastatic phenotype of the cells and furthermore
twist expression is associated with high grade breast
tumors [3,29]. In addition to EMT twist has also other
features which are linked to the growth or metastasis of
tumor cells, i.e. it downregulates the expression of tissue
inhibitors of metalloproteinase 1 (TIMP1) mRNA in
Saos cells [30] promotes angiogenesis by inducing vas-
cular endothelial growth factor (VEGF) and stimulates
cancer cell migration [31,32]. Prevention of twist tran-
scription in breast cancer blocked EMT, invasion and
the development of multidrug resistance induced by
adriamycin [33]. In line with this, expression of twist
has been shown to be prognostically important also in
other types of carcinomas such as cervix [34], hepatocel-
lular [31], esophageal [35] and gastric carcinoma [36].
Nuclear expression of snai1 in the epithelial compart-
ment was seen in 3.1% of cases which is considerably
lower than has been reported in some other types of
tumors. In endometrioid carcinomas, nuclear snail
expression was found in 29% [14] and in ovarian tumors
in 23-38% of cases [14,37]. Snai1 expression has variably
been linked to prognosis in hormone-sensitive ovarian
carcinomas [14,37]. Curiously, there are no extensive
studies on clinical materials in breast cancer. Our pre-
sent experiments reveal that in addition to being rare,
nuclear snai1 expression in breast carcinoma does not
seem to influence patient prognosis. Furthermore, it was
not related to the size of the tumors or to the presence
of metastases. The fact that snai1 was not observed in
stromal cells might suggests that in contrast to some
other tumors it does not play an important role in EMT
of breast carcinoma. Clearer and stronger expression of
snai1 has been detected in squamous cell carcinoma of
the pharynx where stromal expression was associated
with tumor size and prognosis (Jouppila-Mättö A, Tuh-
kanen H, Soini Y, Pukkila M, Närkiö-Mäkelä M, Sironen
R, Virtanen V, Mannermaa A, Kosma V-M: Transcrip-
tion factor Snail 1 expression and poor survival in phar-
yngeal squamous cell carcinoma, submitted). Evidently
tumors of different sites and histology vary in their
expression of snai1.
In our large set of breast carcinomas, no tumors were
found with a positive nuclear expression of zeb1 in
epithelial tumor cells. In contrast, zeb1 was found in
fusiform stromal cells with a 75% proportion. In uterine
tumors, ZEB 1 was expressed in stromal cells of low
grade endometrial adenocarcinomas, but not in tumor
cells [38]. In contrast, aggressive types of endometrial
cancers also showed zeb1 expression in tumor cells
[4,38]. Our results showed a lower expression of zeb1 in
stromal cells in mucinous and medullary carcinomas
than was the case in ductal carcinomas. These tumors
have a slightly better prognosis than breast ductal or
lobular carcinomas [21]. A similar association was
observed for twist in mucinous carcinomas. The results
could suggest that EMT activity would be lower in these
histological types of tumors. Overall, stromal expression
of zeb1 did not associate with the prognosis of the
patients.
Stromal zeb1 expression was significantly lower in
in situ type of breast carcinoma compared to invasive
cases indicating that induction of zeb1 in stromal cells
associates with the invasive phenotype. Some of these
cells could represent transformed tumor cells under-
going EMT. Another proportion of the cell population
could represent stromal fibroblastic cells undergoing
activation of these transcription factors in response to
the growth factors produced by the tumor tissue during
the development of an invasive tumor. This kind of acti-
vation might stimulate stromal cells to transform to
more motile alpha-smooth muscle actin-producing myo-
fibroblasts. In fact, zeb1 serves as a transcriptional acti-
vator inducing genes such as alpha-smooth muscle
actin, vimentin and collagens and heterozygous muta-
tion of zeb1 gene leads to impaired smooth muscle
actin and myosin expression [39].
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Figure 5 Patients with tumors expressing nuclear twist
positivity in the epithelial compartment had a poorer survival
(p = 0.054 log rank, p = 0.013, Breslow, p = 0.025 Tarone-Ware).
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In our set of breast carcinomas stromal expression of
zeb 1 was associated with the estrogen and progesterone
receptor status of the tumors. Previous studies have
revealed that estrogen and progesterone may stimulate
zeb1 expression. In ovarectomised mice, zeb1 was upre-
gulated in uterine stroma and myometrium after proges-
terone or estrogen treatment [38]. Our results indicate
that positive selection of the tumor cells for estrogen
and progesterone receptors is reflected in the upregula-
tion of zeb1 in stromal cells induced by the positive
trophic stimuli of these hormones. Previously it has
been shown that higher amounts of estradiol and
estrone are present in estrogen positive tumors [40]. It
remains to be clarified whether breast epithelial tumor
cells per se do not express zeb1 even in hormone posi-
tive carcinomas. However, in experiments on ten breast
and ovarian carcinoma cell lines, upregulation of the
zeb1 gene was seen in only one cell line, suggesting that
the zeb1 mRNA response in neoplastic cells has become
deranged [4]. This is also reflected in findings on ovar-
ian and uterine non-neoplastic and neoplastic tissues
where zeb1 mRNA levels were associated with the estro-
gen level in non-neoplastic tissue but this association
was lost in neoplastic tissues [4].
Curiously, however, stromal twist expression was not
associated with a poorer survival of the patients nor
was there any relation to tumor size or to the presence
of metastases. Similarly no association was found for
zeb1. The findings may be due to the fact that twist
and zeb1 positive cells in the stroma represent a mix-
ture of cell types, one proportion representing non-
neoplastic activated fusiform fibroblastic cells, the
other being EMT transformed tumor cells. Since these
cells cannot be distinguished properly by morphology
their relationships or even their relative numbers are
difficult to measure. Thus the real quantity of EMT
transformed cells in the stroma cannot be assessed by
zeb1 or twist immunohistochemistry.
Conclusions
Our results reveal that nuclear expression of zeb1, twist
or snai1 is rare in epithelial tumor cell compartment of
breast carcinoma. On the other hand, cells of the stro-
mal compartment displayed abundant expression of
zeb1 and twist but not snai1. Nuclear expression of
twist in epithelial tumor cells was associated with a
poorer prognosis of the patients indicative of its impor-
tance in the spread of breast carcinoma. However, stro-
mal positivity of zeb1 or twist was not, however,
associated with the size of the tumors, metastatic activ-
ity or prognosis of the patients. This may reflect the fact
that the stromal compartment contains a mixture of
zeb1 and twist positive cells, some representing EMT
transformed neoplastic cells, the others being non-neo-
plastic activated fibroblasts.
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